Compare Recursion Pharmaceuticals Inc (RXRX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SOLAI Limited — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.4× SOLAI Limited's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and SOLAI Limited for 40 Days on average.
| RXRX | SLAI | |
|---|---|---|
Market Cap | $2.14B | $880.09M |
Volume | 30,789,535 | 122,720 |
Sector | Health | Technology |
52-Week High | $6.79 | $21.63 |
52-Week Low | $2.84 | $2.74 |
Typical Hold Time | 23 Days | 40 Days |
Enterprise Value | $1.66B | $879.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
SLAI trades at $3.72 with no recent price movement. The stock shows a bullish technical signal despite concerning fundamentals, including negative profit margins (-134.76% net income margin) and declining revenue from $57M in 2022 to $23M in 2025. The company received a delisting notice from NYSE in July 2026, creating significant uncertainty. Cash flow remains negative at -$1.47M, though the P/B ratio of 0.35 suggests potential undervaluation based on book value.
Outlook remains highly speculative given delisting proceedings and persistent losses. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment. Investment opportunity exists only for risk-tolerant investors betting on turnaround potential, while major risks include delisting execution, continued cash burn, and competitive pressures in the AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
